Network Medicine Approaches for Revealing Shared Molecular Mechanisms Between Chronic Diseases and Natural Compound Therapies
Keywords:
network medicine, chronic disease comorbidity, natural compounds, disease modules, polypharmacology, synergistic interactionsAbstract
Chronic diseases such as type 2 diabetes, cardiovascular disease, and neurodegeneration frequently co-occur, yet their shared molecular determinants remain poorly resolved by single-disease reductionism. Natural compounds offer a multimodal therapeutic logic that is difficult to reconcile with target-centric pharmacology. This manuscript develops a network medicine framework for identifying the molecular mechanisms that couple chronic disease modules to natural-compound target sets. The contribution is a formal analytical pipeline that integrates disease-gene module construction, compound-target network projection, module-level proximity and convergence analysis, community-level decomposition of polyphenol and alkaloid target sets, and an interaction-context layer that distinguishes intrinsic target topology from pathway-mediated crosstalk. We define a convergent module score for quantifying shared etiological architecture across disease pairs and a compound-mediated convergence index for ranking natural products by their capacity to engage disease module intersections rather than isolated hubs. The analysis specifies the conditions under which topological proximity reflects mechanistic overlap, including module boundary sensitivity, hub bias, and the distinction between physical and functional interactions. We also show why natural compounds require community-aware rather than single-target evaluation and how synergistic combinations can be identified from overlapping but non-identical module neighborhoods. The framework provides a reproducible conceptual basis for experimental prioritization and clarifies when network-derived claims about shared mechanisms are defensible versus overinterpreted. Its significance lies in connecting comorbidity biology with polypharmacological natural product research through explicitly stated, testable, and falsifiable network criteria.
References
1. Barabási, A.-L., Gulbahce, N., & Loscalzo, J. (2011). Network medicine: A network-based approach to human disease. Nature Reviews Genetics, 12(1), 56-68.
2. Loscalzo, J., & Barabási, A.-L. (2011). Systems biology and the future of medicine. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 3(3), 253-261.
3. Menche, J., Sharma, A., Kitsak, M., Ghiassian, S. D., Vidal, M., Loscalzo, J., & Barabási, A.-L. (2015). Uncovering disease-disease relationships through the incomplete interactome. Science, 347(6224), 1257601.
4. Newman, D. J., & Cragg, G. M. (2020). Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. Journal of Natural Products, 83(3), 770-803.
5. Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., & Supuran, C. T. (2021). Natural products in drug discovery: Advances and opportunities. Nature Reviews Drug Discovery, 20(3), 200-216.
6. Hopkins, A. L. (2008). Network pharmacology: The next paradigm in drug discovery. Nature Chemical Biology, 4(11), 682-690.
7. Li, S., & Zhang, B. (2013). Traditional Chinese medicine network pharmacology: Theory, methodology and application. Chinese Journal of Natural Medicines, 11(2), 110-120.
8. Goh, K.-I., Cusick, M. E., Valle, D., Childs, B., Vidal, M., & Barabási, A.-L. (2007). The human disease network. Proceedings of the National Academy of Sciences, 104(21), 8685-8690.
9. HerbSyner_Finder: a network community-based model for identifying synergistic combinations from herbal medicines and complex systems. Targetome. 2026;2(2):0-0. doi: 10.48130/targetome-0026-001
10. Guney, E., Menche, J., Vidal, M., & Barabási, A.-L. (2016). Network-based in silico drug efficacy screening. Nature Communications, 7, 10331.
11. Cheng, F., Kovács, I. A., & Barabási, A.-L. (2019). Network-based prediction of drug combinations. Nature Communications, 10, 1197.
12. Yildirim, M. A., Goh, K.-I., Cusick, M. E., Barabási, A.-L., & Vidal, M. (2007). Drug-target network. Nature Biotechnology, 25(10), 1119-1126.
13. Vidal, M., Cusick, M. E., & Barabási, A.-L. (2011). Interactome networks and human disease. Cell, 144(6), 986-998.
14. Zitnik, M., Agrawal, M., & Leskovec, J. (2018). Modeling polypharmacy side effects with graph convolutional networks. Bioinformatics, 34(13), i457-i466.
15. Hsin, K.-Y., Ghosh, S., & Kitano, H. (2013). Combining machine learning systems and multiple docking simulation packages to improve docking prediction reliability for network pharmacology. PLoS ONE, 8(12), e83922.
16. Zhang, B., & Horvath, S. (2005). A general framework for weighted gene co-expression network analysis. Statistical Applications in Genetics and Molecular Biology, 4, Article17.
17. Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013). Structure and dynamics of molecular networks: A novel paradigm of drug discovery. Pharmacology & Therapeutics, 138(3), 333-408.
18. Ideker, T., & Sharan, R. (2008). Protein networks in disease. Genome Research, 18(4), 644-652.
19. Furlong, L. I. (2013). Human diseases through the lens of network biology. Trends in Genetics, 29(3), 150-159.
20. Pujol, A., Mosca, R., Farrés, J., & Aloy, P. (2010). Unveiling the role of network and systems biology in drug discovery. Trends in Pharmacological Sciences, 31(3), 115-123.
21. Zhou, X., Menche, J., Barabási, A.-L., & Sharma, A. (2014). Human symptoms-disease network. Nature Communications, 5, 4212.
22. Lee, D.-S., Park, J., Kay, K. A., Christakis, N. A., Oltvai, Z. N., & Barabási, A.-L. (2008). The implications of human metabolic network topology for disease comorbidity. Proceedings of the National Academy of Sciences, 105(29), 9880-9885.
23. Barabási, A.-L., & Oltvai, Z. N. (2004). Network biology: Understanding the cell's functional organization. Nature Reviews Genetics, 5(2), 101-113.
24. Kitano, H. (2002). Systems biology: A brief overview. Science, 295(5560), 1662-1664.
25. Schadt, E. E. (2009). Molecular networks as sensors and drivers of common human diseases. Nature, 461(7261), 218-223.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 International Journal of Clinical and Translational Medicine

This work is licensed under a Creative Commons Attribution 4.0 International License.
This article is published under the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



